Clinical heterogeneity within t(12;21) or TEL/AML1-positive ALL (25% of childhood common/preB ALL) indicates that additional genetic changes might contribute to outcome. We studied the relation between additional genetic changes in TEL(ETV6) and AML1(RUNX1) (FISH), drug sensitivity (MTT assay) and clinical outcome in 143 DCOG and COALL-treated t(12;21)-positive ALL patients. Additional genetic changes in TEL and AML1 were present in 83% of the patients, and consisted of (partial) deletion of the second TEL gene (70%), an extra AML1 gene (23%) or an extra der(21)t(12;21) (10%). More than one additional change was observed in 20%. Disease-free survival (pDFS) of DCOG patients without additional genetic changes (4 years pDFS7s.e. 53717%) and of those with an extra der(21)t(12;21) (60722%) is poorer than that of compared to patients with other additional genetic changes in TEL or AML1 (7976%; P-trend ¼ 0.02). This was mainly due to the occurrence of early relapses within 2.5 years after the first diagnosis. Similar observations were found in the COALL cohort, albeit not significant owing to limited follow-up. Multivariate analysis including age, WBC and genetic abnormalities in TEL and/or AML1 showed that especially, in vitro resistance to prednisolone (hazard ratio 5.78, 95% CI 1.45-23.0; P ¼ 0.01) is an independent prognostic factor in DCOG-and COALL-treated t(12;21)-positive ALL.
Introduction
The t(12;21)(p13;q22) occurs in B25% of childhood acute lymphoblastic leukemia (ALL), and is restricted to precursor Bcell lineage leukemia. The t(12;21) involves fusion of the TEL(ETV6) gene at chromosome 12p13, with the AML1(RUNX1) gene at chromosome 21q22. This translocation fuses the 5 0 terminus of the TEL gene (residues 1-336) in frame, with almost the entire coding sequence (residues 21-480) of the AML1 gene. The breakpoint most often occurs in intron 5 of TEL, and intron 1 of AML1. A frequent translocation variant results in fusion between intron 5 of TEL and intron 2 of AML1. Both TEL and AML1 are frequent targets of chromosomal translocations in a variety of myeloid and lymphoid leukemias.
1,2 TEL contains an N-terminal pointed (PNT) dimerization domain that mediates homodimerization. 3, 4 The C-terminal DNA-binding domain homologous to all Ets proteins, recognizes a purine-rich GGAA/T core motif within promoters and enhancers of various genes. 5 TEL has a role in both angiogenesis and hematopoiesis. 6 AML1 encodes a transcription factor that binds the enhancer core sequence TGT/cGGT through its N-terminal Runt homology domain (RHD). 7 The DNA-binding affinity of AML1 is increased by heterodimerization through the RHD with the core binding factor (CBF) b protein, forming the CBF. Transcriptional activation occurs through the C-terminal transactivation (TA) domain. CBF is essential for definitive hematopoiesis of all lineages. 1 The translocation fusion product TEL/AML1 contains the PNT domain of TEL and the RHD, and TA domain of AML1.
Several studies have investigated the prognostic value of t(12;21) positive ALL (reviewed in Loh and Rubnitz 8 ). In general, t(12;21)-positive ALL is associated with a good prognosis. However, conflicting data on the percentage of patients entering relapse and the proportion of t(12;21)-positive cases at relapse have been reported. 8 Overall, the reported prognostic relevance of t(12;21) seems to depend on the intensity of the treatment protocol. A possible explanation for this finding can be ascribed to the fact that t(12;21)-positive ALL cells are in vitro more sensitive to L-Asparaginase (L-Asp) than t(12;21) negative ALL cells. 9, 10 However, within the t(12;21)-positive ALL group, large interindividual differences in cellular in vitro sensitivity to L-Asp were found. The clinical heterogeneity in response to therapy as well as the large heterogeneity in in vitro sensitivity to L-Asp suggests that additional genetic changes might be important for the differences in drug sensitivity and clinical outcome. Approximately, 70% of t(12;21)-positive ALL cases also show loss of the second TEL allele. 11, 12 Trisomy 21 and duplication of the der(21)t(12;21) are also found in t(12;21)-positive patients, with the latter apparently being more common in relapsed cases. [13] [14] [15] [16] However, the number of patients screened in these studies is limited. The prognostic significance of additional genetic abnormalities in TEL and AML1 is therefore unknown. We retrospectively studied the incidence of additional genetic changes in the TEL and AML1 genes, and their relationship with drug sensitivity and clinical outcome in 143 t(12;21)-positive children with ALL.
Materials and methods

Patient samples
Bone marrow and/or peripheral blood samples from 343 untreated children with common/pre B-ALL at initial diagnosis were collected at the Erasmus MC, Sophia Children's hospital, the Dutch Childhood Oncology Group (DCOG) and the German COALL study group. Within 24 h after sampling, mononuclear cells were isolated and contaminating nonleukemic cells were eliminated as described earlier. 17 All resulting samples contained X90% leukemic cells, as determined morphologically on May-Grü nwald-Giemsa (Merck, Darmstadt, Germany) stained cytospins.
FISH analysis
In total, 272 Erasmus MC, Sophia Children's Hospital and DCOG common/pre B-ALL patients were retrospectively analyzed for the presence of t(12;21) by FISH, whereas the t(12;21) positivity of 71 COALL patients was already known by RT-PCR. The FISH protocol was based on that described previously. 18 The t(12;21) positivity was determined on cryopreserved cytospins, with dual-colored FISH using a digoxigenin-labeled cosmid from intron 1 to exon 2 of TEL (50F4), together with a biotinylated cosmid for the first five exons of AML1 (C0664) (a kind gift of Dr N Sacchi, University of Milan, Italy 19 ) (Figure 1 ). Probe 50F4 was detected with Texas Red-labeled a-digoxigenin, and probe C0664 with avidin-FITC. In t(12;21)-positive patients, a yellow fusion spot will be seen denoting the der(21)t(12;21), one green signal for the normal AML1 on chromosome 21, and one red signal for the normal TEL on chromosome 12. Two green spots next to the yellow fusion spot indicate an extra copy of AML1, whereas the absence of a single red signal indicates a deletion of TEL. To determine the size of the deletion of the second TEL allele in t(12;21)-positive patients, additional dualcolored FISH experiments were performed using TEL cosmid probes located at the 5 0 (179A6-biotinylated) and 3 0 (54D5-digoxigenin labeled) part of the TEL gene (Figure 1) . If the complete nontranslocated TEL gene is deleted, only one yellow fusion spot spanning exon 1a-5 of TEL on the der(21)t(12;21) and a red signal spanning exon 6-8 of TEL on der(12)t(12;21) will be present. If the nontranslocated TEL gene is only partially deleted, two yellow fusion spots are visible, one derived from der(21)t (12;21) , and the other from the non-translocated TEL gene. In addition, a red signal from the der(12)t(12;21) will be present. Partial deletion of TEL was indicated by a loss of the 50F4 signal, whereas the 179A6 and 54D5 fusion signal remained visible. All TEL cosmids were a kind gift of Professor Dr P Marynen, Human Genetics, University of Leuven, Belgium. 20 In all instances, two independent observers each examined 100-300 interphase nuclei.
In vitro L-Asp, prednisolone (Pred) and vincristine (VCR) cytotoxicity assay
In vitro L-Asp, Pred and VCR cytotoxicity was determined using the MTT assay as described previously. 17 Briefly, 100 ml aliquots of cell suspension (1.6 Â 10 5 cells; 490% leukemic cells) were exposed to six duplicate concentrations of L-Asp (Paronal, Christiaens, Breda, The Netherlands) ranging from 0.0032 to 10 IU/ml, Pred (prednisoloni natrii phosphas, Bufa BV, Uitgeest, The Netherlands) ranging from 0.08 to 250 mg/ml and VCR (vincristinesulphate, TEVA Pharma BV, Mijdrecht, The Netherlands) ranging from 0.049 to 50 mg/ml. Control cells were cultured without L-Asp, Pred or VCR. After incubating the plates for 4 days at 371C in humidified air containing 5% CO 2 , 10 ml of 3-(4,5-dimethylthiazol-2 yl)-2,5-diphenyltetrazoliumbromide (MTT, 5 mg/ml; Sigma Aldrich, Zwijndrecht, The Netherlands) was added. During a 6 h incubation, the yellow MTT tetrazolium salt was reduced to purple-blue formazan crystals by viable cells only. Samples with X70% leukemic cells in the control wells after 4 days of culture and an optical density higher than 0.050 arbitrary units (adjusted for blank values) were used to calculate the concentration of drug lethal to 50% of the cells (LC 50 ).
Statistics
In all patient samples, one major aberrant clone representing more than 80% of all leukemic cells was observed. The size of subclones, if present, was small, and accounted together with normal cells only for less than 20% of the total population. In this study, we therefore divided the samples, according to the major clone present in patients, that is (1) without additional genetic changes in TEL or AML1, (2) with an extra der(21)t(12;21), or (3) with other additional genetic changes such as a deletion of TEL and/or an extra copy of AML1. Probability of disease-free survival (pDFS) was calculated from the date of diagnosis to the date of relapse or nonresponse (event) or last contact (censored), according to the method of Kaplan-Meier 21 and standard errors (s.e.) were calculated according to the Greenwood formula. 22 The prognostic value of additional deletions in TEL and/or AML1 genes was analyzed by the a Cox proportional hazard regression model, and was used for both univariate and multivariate analyses of potential risk factors. Differences in the distribution of variables between two groups of patients were analyzed using the Mann-Whitney U or w 2 -test. Differences in the distribution of variables between more than two groups were analyzed using the Kruskal-Wallis test. Statistical tests were performed using SPSS 11.0 at a twotailed significance level of 0.05.
Results
In all, 143 t(12;21)-positive cases were analyzed for additional genetic changes in TEL and AML1, by extensive FISH analysis. Of all the patients, 83% (118/143) showed one or more additional genetic changes ( Figure 2 ). These additional genetic changes could be divided into a complete deletion of the second TEL allele (62%; 88/143), a partial deletion of the second TEL allele (8%; 12/143), an extra copy of AML1 (23%; 33/143) and an extra der(21)t(12;21) indicating an extra fusion product (10%; 15/143). Of all t(12;21)-positive ALL patients, 20% (28/143) had more than one additional genetic abnormality in TEL and AML1.
The 143 t(12;21)-positive patients consisted of 72 Dutch DCOG patients and 71 German COALL patients. Patient characteristics did not differ between the two treatment groups, except that the follow-up time of COALL patients was shorter (median 2.9 years, range 0.3-7.1 years) and, as a consequence, the number of relapses was lower (five relapses) than that of DCOG patients (median follow-up time 6.0 years, range 1.6-12.8 and 16 relapses; Po0.0001 for comparison of pDFS curves between both study groups). Kaplan-Meier curves of patients without additional changes in TEL or AML1, patients with an extra der(21)t(12;21), and patients with additional changes in TEL or AML1 other than an extra der(21)t(12;21) are shown in Figure 3 . In DCOG treated patients, the absence of additional genetic changes in TEL or AML1 (4 years pDFS7s.e. of 53%717%) or the presence of an extra der (21)t(12;21) (4 years pDFS7s.e. of 60722%) are linked to a poorer prognosis than that of t(12;21)-positive patients with additional genetic changes in TEL or AML1 (4 years pDFS7s.e. of 7976%; Figure 3a ; trend ¼ 0 3A; P-trend ¼ 0.02). Moreover, in patients without additional genetic changes or with an extra der(21)t(12;21), all six events (i.e. nonresponse or relapse) occurred early, that is within 2.5 years after first diagnosis, compared to patients with additional genetic changes (4 out of 11 events o2.5 years; w 2 ¼ 6.49, P ¼ 0.04). In the COALL group, the three abovementioned genetic subgroups reflecting the occurrence of additional genetic changes in TEL and/or AML1 were not associated in a statistically significant way, with prognosis, although, the same relative trend in the curves was seen in COALL compared to DCOG patients (Figure 3b ; P-trend ¼ 0. (Figure 4a ). However, we found t(12;21)-positive ALL patients with an extra der(21)t(12;21) to be 123-fold more resistant to Pred than patients without an extra der(21)t(12;21) (P ¼ 0.004; Figure 4a ) and even 850-fold more resistant to Pred than patients with an extra AML1 indicative for an extra chromosome 21 (P ¼ 0.001; data not shown). In vitro Pred resistance was significantly related to an unfavorable prognosis within t(12;21)-positive DCOG patients (P-trend ¼ 0.03; Figure 4b , Table 1 ) and the same order in curves (but not significant) was found among COALL patients (Figure 4c , Table 1 ). Study-groupstratified univariate analysis showed that Pred resistance was also a poor prognostic variable in the combined group of DCOG and COALL patients (P-trend ¼ 0.02). Multivariate analysis including age, white blood cell count and the three subgroups Table 1 , study-group-stratified analysis).
Discussion
In our present study, the incidence of additional genetic changes in the TEL and AML1 genes in 143 children with t(12;21)-positive ALL at initial diagnosis is 83%. A (partial) deletion of the nontranslocated TEL allele (70%) occurred most frequently followed by the presence of an extra copy of AML1 (23%) and an extra der(21)t(12;21) (10%). Moreover, 20% of the t(12;21)-positive patients had more than one additional genetic change in TEL or AML1. This incidence is in concordance with reports of additional genetic abnormalities in lower numbers of patients.
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In t(12;21)-positive ALL, an extra der(21)t(12;21) has been reported to be more frequently present in relapsed cases. [13] [14] [15] [16] In the present study, we show in a univariate analysis that even in a small number of patients, the presence of this additional abnormality at diagnosis is linked to an unfavorable long-term clinical outcome. Furthermore, we observed that the absence of additional genetic changes in TEL or AML1 is related to a poor prognosis in t(12;21)-positive ALL. These observations were significant in DCOG-treated patients, whereas a similar trend was seen for COALL-treated cases (Figure 3 ) albeit not significant due to the relatively short follow-up and, hence, a smaller number of events that had been occurred. The favorable outcome associated with the presence of deletions of the short arm of chromosome 12 (including the TEL gene) is in correspondence with previous reports in childhood ALL. 23, 24 These data and our present study are in contrast to the data reported by Attarbaschi et al., 25 in which a deletion of TEL in t(12;21)-positive ALL was linked with an unfavorable prognosis. A possible explanation may be the differences in definition of an event (event is defined as relapse or nonresponse in our study whereas it is defined as a failure to achieve remission, relapse at any site, death during continuous remission or the development of a secondary malignancy in the study of Attarbaschi et al.
25
) and in the treatment protocol that was used (DCOG ALL-7/8/9 and COALL-92/97 in this study, and ALL-BFM-A 1990/1995 in the Attarbaschi study). Our data further indicated that an extra der(21)t(12;21) was linked to Pred resistance. Multivariate analysis indicated that especially, prednisolone resistance is independently linked to an unfavorable outcome whereas the absence of additional changes in TEL and AML1 is of borderline significance in t(12;21)-positive ALL.
Conflicting data (reviewed by Loh and Rubnitz 8 ) on the prognostic value of t(12;21) might be due to differences in the amount of L-Asp and the schedule in which L-Asp is given as t(12;21)-positive ALL is highly sensitive to L-Asp 9,10 , and L-Aspsensitive patients have a more favorable outcome. 26 Both DCOG and COALL study groups use similar Escherichia coli L-Asp preparations, but the cumulative dosage of L-Asp used in the COALL treatment protocol is higher. It is possible that a general intensification of therapy, not only by L-Asp but also by other drugs, might contribute to the fact that in some recent protocols, patients with t(12;21)-positive ALL have a favorable outcome. 27 An intensified treatment protocol may also explain the difference in event-free survival of t(12;21)-positive ALL patients between the DCOG and COALL group (5-year eventfree survival of 73 and 80%, respectively). 28, 29 The fact that the prognostic value of t(12;21) positive ALL may depend on the therapy that is being given is further illustrated by the fact that Table 1 Prognostic relevance of genetic changes in TEL and/or AML1 and prednisolone resistance in t(12;21)-positive ALL patients Hazard ratio with 95% CI and P-value of patients being intermediate sensitive or resistant to Prednisolone, compared with the reference group of patients being sensitive to prednisolone. e Multivariate analysis based on 112 patients, for which all variables included in the model were known. In this cohort, a total of 16 events (i.e. relapses) occurred. This multivariate analysis was performed using Cox proportional hazard regression analysis with stratification for study group (DCOG and COALL).
the presence of the TEL/AML1 fusion has no prognostic value in the low-risk arm of the COALL-97 protocol, whereas t(12;21)-positive patients treated according to the high-risk arm of this protocol have a more favorable prognosis than that of t(12;21)-negative patients (Professor Dr GE Janka-Schaub, personal communication).
A relapse in t(12;21)-positive ALL is thought to occur after completion of therapy, that is, 42.5 years after first diagnosis. 8 As shown in Figure 3 , the majority of relapses in our series of t(12;21)-positive ALL occurred after 2.5 years of diagnosis. However, the absence of additional genetic changes in TEL or the AML1, or presence of an extra der(21)t(12;21) in t(12;21)-positive patients identified patients at higher risk for early events ( Figure 3) ; all events in these small subgroups were within 2.5 years after first diagnosis. Early relapses may occur as a result of regrowth of leukemic cells despite chemotherapy or insufficient clearance from the bone marrow, during the first months of therapy. 30 Studies show that the t(12;21) rearrangement already occurs in utero and secondary leukemogenic events subsequently occur later on during childhood. 31, 32 Continuing differentiation processes lead to a variety of immune receptor rearrangements in individual cells of the t(12;21)-positive preleukemic clone, resulting in a heterogenous population of t(12;21)-positive cells at the time of clinical presentation of the disease. Rapid and sustained disappearance of the dominant leukemia clones and a slow response of the smaller (preleukemic) clones upon first chemotherapy has been observed in t(12;21)-positive ALL patients. 33, 34 Combination therapy may fail to eradicate the preleukemic clone, which may, after acquiring a new second leukemogenic hit, give rise to a new leukemia that is (falsely) being interpreted as a relapse of the original leukemia. 35 It is of interest to study whether the early relapses that occur amongst patients without additional genetic abnormalities in TEL or AML1, or with an extra copy of der(21)t(12;21), may be due to other secondary leukemogenic hits rather than the original leukemia.
In concordance with a current model proposing an order of molecular events needed for leukemogenesis, 36,37 the expression of TEL/AML1 alone is not sufficient for the induction of hematomalignancies in transgenic mice. 38, 39 . As the second TEL allele is most frequently deleted in t(12;21)-positive ALL, it is speculated that wild-type TEL acts as a tumor-suppressor gene and its deletion in t(12;21)-positive ALL is the second hit required for leukemogenesis. However, 30% of the t(12;21)-positive ALL patients do not show a deletion of TEL, indicating that another genetic abnormality is necessary for leukemogenesis. TEL itself is known to cooperate with other transcriptional factors in transcriptional regulation of many genes. 6 The TEL/ AML1 protein structure seems an essential element in leukemogenesis because of the high affinity for transcription corepressors such as N-CoR, mSin3 and HDAC3, and the ability of this complex to influence the transcriptional activity of other genes. 40, 41 The fusion product TEL/AML1 competes with AML1 for binding to enhancer core sequences TGTcGGT via the RHD. 42 A disbalance between TEL, AML1 and TEL/AML1 may explain the observed poor prognosis associated with an extra copy of der(21)t(12;21) and the absence of abnormalities in the second TEL and AML1 genes. When the nontranslocated TEL gene is intact, a heterodimer with TEL/AML1 can be formed. 43 Both this heterodimer as well as a TEL/AML1 homodimer may increase the DNA-binding capacity of TEL/ AML1, thereby shifting the balance into transcriptional repression of AML1 target genes. A deletion of TEL or an extra copy of AML1 may oppose the transcriptional repression of TEL/AML1 dimers.
Patients with an extra der(21)t(12;21) are more resistant to Pred than patients with an extra copy of AML1 (which is often associated with an extra copy of chromosome 21). This suggests that the TEL/AML1 fusion is more linked to Pred resistance than other genes located on 21q. In addition, these data imply that TEL/AML1, beside AML1-targeted genes, may also compete with the glucocorticoid-glucocorticoid receptor complex for binding to glucocorticoid-responsive genes. Also, the possibility remains that additional genes on 12p may contribute to the Pred resistance in patients with an extra der(21)t(12;21).
In conclusion, 83% of patients with t(12;21)-positive ALL have additional genetic changes in the TEL and AML1 genes. An extra der(21)t(12;21) and the absence of additional genetic abnormalities in these genes are associated with a poorer outcome in t(12;21)-positive ALL, which was mainly explained by the fact that these patients suffer from early relapses within 2.5 years after first diagnosis. An extra copy of der(21)t(12;21) was linked to 4100-fold Pred resistance compared to the remaining group. Multivariate analysis including known risk factors and the occurrence of genetic changes in TEL and/or AML1 showed that especially, in vitro resistance to Pred is an independent prognostic factor in t(12;21)-positive ALL.
